Steve Godber – Chairman
BA
Steve joined the board of the company in 2013 to oversee the company’s product and market development phase. He is a non-executive Director, and Chairman of both viO HealthTech Limited and viO HealthTech Inc., the company’s wholly owned US subsidiary. Steve has over 25 years experience as a Chairman and CEO, mainly in healthcare companies. He is currently Chairman of Lifelines Ltd. He was previously Chairman of The Magstim Company Ltd, and CEO of Vickers Medical and Forum Bioscience.
Rob Milnes – CEO
BA Hons (Business) DipM
Rob has over 30 years experience in financing and bringing ground-breaking medical technology and software to global markets, with the past 20 years focussed on women’s health. Co-inventor of 6 OvuSense patents and co-author of several clinical publications, he is also CEO of viO HealthTech Inc., the company’s wholly owned US subsidiary. Rob has worked for Roche, Oxford Instruments, and was formerly a member of the Operations Board of Huntleigh Healthcare following the successful sale and integration of the Sonicaid Fetal Monitoring and Medilog Cardiology businesses. He brings extensive experience in international sales & marketing, M&A, sub-contract manufacturing, finance and systems.
Rob Jones – Investor Director
BA MA
Rob Jones is the Investor Director representing Foresight Group on the viO HealthTech Board. Rob joined Foresight in 2016 and currently works as an Investment Manager in the Manchester office. Rob is responsible for sourcing and executing investments and providing ongoing strategic and financial advice to existing portfolio companies. Prior to joining Foresight Rob worked at EY as an Associate Director where he focused on advising mid-market Private Equity firms and corporates on a wide range of transactions. He trained with RSM Tenon where he spent the majority of his time advising owner managed businesses on company sales and fund raising.
Derek Pink – Director
Following a career in the city, Derek Pink became an angel investor a decade ago. He concentrates on a limited portfolio and has made four tech company investments including a successful exit to date. He is the largest independent investor in the Company in the past year having seen a potential solution in OvuSense to an unmet need in the infertility market, where treatment options are time consuming, expensive and invasive. He represents the interests of the viO HealthTech independent shareholders on the board.